Builds an automated, robotic "Cell Shuttle" platform for GMP-compliant manufacturing of cell therapies, operating as an integrated development and manufacturing organization for biopharma clients.

San Carlos CA. Cell-free DNA synthesis — produces long, complex DNA rapidly without cloning. IQT Summer 2025 investment. ENFINIA platform. Enables synthetic biology workflows at speed. National security applications: biodefense, biodetection, rapid vaccine/countermeasure development.

AI small-molecule drug discovery; GEMS foundation models; partnerships incl. Gilead and Incyte; raised over USD 300M.

Cloud software for life sciences. Pleasanton CA. Founded 2007. NYSE: VEEV. $40B+ market cap. Dominant in pharma CRM and regulatory software.